Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature remarks on Braveheart Bio's cardiac myosin inhibitor program and the global clinical development of BHB-1893 in patients with obstructive HCM and non-obstructive HCM from Management and the following speakers: * Anjali Owens, M.D., Associate Professor of Medicine and Medical Director, Penn Center for Inherited Cardiovascular Disease, Perelman School of Medicine at the University of Pennsylvania * Mariko Harper, M.D., Medical Director, Hypertrophic Cardiomyopathy Center of Excellence, Virginia Mason Franciscan Health A live question-and-answer session will follow the formal presentations.